Abstract | BACKGROUND & AIMS: METHODS: RESULTS: Seven patients developed sustained virologic response. At baseline, HBsAg correlated well with both log (cccDNA) (r = 0.54, P = .004) and log [total intrahepatic HBV DNA] (r = 0.43, P = .028). The median reduction of HBsAg was 1287 IU/mL (range, 12,223-26,763 IU/mL). Reduction of HBsAg has good correlation with reduction in log [cccDNA] (r = 0.68, P < .0001) and reduction in log [total intrahepatic HBV DNA] (r = 0.65, P < .0001). Patients with lower baseline cccDNA, intrahepatic HBV DNA, and HBsAg level but not serum HBV DNA level tend to develop sustained virologic response. A baseline HBsAg level of less than 10,000 IU/mL had sensitivity, specificity, and positive and negative predictive values for sustained virologic response of 86%, 56%, 43%, and 92%, respectively. CONCLUSIONS: Serum HBsAg levels correlate well with the cccDNA and intrahepatic HBV DNA. Low pretreatment HBsAg is better than HBV DNA to predict good response to peginterferon and lamivudine treatment.
|
Authors | Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Ada Mei-Ling Tse, Chi-Hang Tse, Angel Mei-Ling Chim, Hoi-Yun Chan, Grace Lai-Hung Wong, Joseph Jao-Yiu Sung |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 5
Issue 12
Pg. 1462-8
(Dec 2007)
ISSN: 1542-7714 [Electronic] United States |
PMID | 18054753
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- DNA, Viral
- Drug Carriers
- Hepatitis B Surface Antigens
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
- Reverse Transcriptase Inhibitors
- Lamivudine
- Polyethylene Glycols
- peginterferon alfa-2b
|
Topics |
- Adult
- Antiviral Agents
(therapeutic use)
- Biopsy
- DNA, Viral
(analysis)
- Drug Carriers
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepatitis B Surface Antigens
(analysis, drug effects)
- Hepatitis B virus
(drug effects, genetics, immunology)
- Hepatitis B, Chronic
(drug therapy, virology)
- Humans
- Interferon alpha-2
- Interferon-alpha
(therapeutic use)
- Lamivudine
(therapeutic use)
- Liver
(pathology, virology)
- Male
- Polyethylene Glycols
- Polymerase Chain Reaction
- Recombinant Proteins
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Sensitivity and Specificity
- Treatment Outcome
|